GLP-1 and Intestinal Diseases.

Abstract

Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

• Authors: Jenna Elizabeth Hunt, Jens Juul Holst, Palle Bekker Jeppesen, Hannelouise Kissow
• Journal: Biomedicines (Biomedicines) Vol. 9 Issue 4 (Apr 05 2021) ISSN: 2227-9059 [Print] Switzerland
• PMID: 33916501 (Publication Type: Journal Article, Review)